L'Oréal and Symatese have announced the strengthening and expansion of their strategic partnership with the signing of new long-term research and development agreements in the field of biomaterials.
The two companies have been collaborating in the field of tissue and cell engineering for over 20 years. Episkin S.A., a subsidiary of the L'Oréal group, is today the world leader in the production of reconstructed human tissues, part of which is based on know-how developed historically with Symatese, a company renowned for the quality of its technological platforms for the extraction and transformation of biopolymers intended for multiple therapeutic indications. These reconstructed tissues have become a benchmark in biomedical research and a key tool for various industries as an alternative evaluation method to animal testing. L'Oréal and Symatese aim to continue combining their respective expertise to explore new scientific avenues in the field of biomaterials designed for human tissue physiology.
"Building on our long-standing collaboration with Symatese, we are delighted to embark on this new stage in our scientific partnership, which supports the exploration of new horizons of discovery and innovation to offer men and women around the world even greater performance in our beauty offering and in the care of their skin. This collaboration will benefit from Symatese's cutting-edge expertise in the field of biomaterials, expertise now recognized internationally by the quality of products marketed in the therapeutic field".says Barbara Lavernos, Executive Vice President, Research, Innovation and Technology at L'Oréal.
Jean-Paul Gérardin, Managing Director of Symatese, said: "We are very pleased to have established this new partnership with L'Oréal, whose extensive expertise in skin physiology, clinical performance markers and alternative assessment methods perfectly complements our know-how in the design and industrialization of biomaterials. We therefore look forward to great scientific advances and innovative products for our patients."
